Dapagliflozin Propanediol Monohydrate API
| Name of Product | Dapagliflozin Propanediol Monohydrate API |
|---|---|
| CAS No | 960404-48-2 |
| Therapeutic use:- | SGLT2 inhibitor – type 2 diabetes management |
| Form:- | API Powder |
| Grade | USP/IH |
| Status | Commercial |
Product Overview
Dapagliflozin Propanediol Monohydrate (1056036-79-0) is an active pharmaceutical ingredient (API).
It belongs to the class known as SGLT2 inhibitors. They function in the kidneys.
They block the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules of the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
The excess sugar then leaves the body through urine.
There are additional effects, as per studies. It can cause weight reduction. It can lower blood pressure.
It lowers the risk of heart complications, too. In some cases, it protects the kidneys.
The drug is an off-white or white crystalline powder. It dissolves in most solvents.
It is stable under proper storage conditions.Â
Therapeutic Applications
It is used most frequently in type 2 diabetes. It is blended with sulfonylureas, metformin, or insulin.
It is beneficial as it lowers blood sugar through a unique renal mechanism, distinct from other antidiabetic agents.
It also helps in chronic kidney disease (CKD). CKD patients can reduce the progression of kidney impairment while taking this drug.
It can delay the progression to dialysis in CKD patients. It is also used in heart failure with reduced ejection fraction (HFrEF).
It reduces mortality from heart disease.
Specification Parameters
Packaging & Storage
Packaging Options:
Storage Instructions:
Why Choose Us
Actiza is a distributor of Dapagliflozin Propanediol Monohydrate and other APIs.
We enjoy the confidence of many international associates.